Lifestance Health Group Inc (LFST)
Official siteHEALTHCARE • MEDICAL CARE FACILITIES • NASDAQ
Market Cap: $5.35B
Last updated: Nov 17, 2026 at 11:06 AM ET
Lifestance Health Group Inc (LFST) P/E Ratio & Valuation History
Lifestance Health Group (LFST) trades at 52.0x trailing earnings and 3.3x sales. Its P/B of 3.7x is above its 5-year median of 1.8x. Its forward P/E is 61.4x. The median P/E across 12 similar companies is 24.2x.
Current Multiples
Its forward P/E is above its trailing P/E, which implies earnings per share about 15.3% lower over the next year. Its free cash flow yield is 3.2%.
| Multiple | Value |
|---|---|
| P/E (trailing) | 52.0x |
| Forward P/E | 61.4x |
| Price to sales | 3.3x |
| Price to book | 3.7x |
| EV/EBITDA | 35.5x |
| Price to FCF | 30.8x |
| EV/FCF | 31.0x |
| PEG | N/A |
| FCF yield | 3.2% |
Historical Medians
| Multiple | Current | 5-year median | 10-year median |
|---|---|---|---|
| P/B | 3.7x | 1.8x | N/A |
Valuation History
Over the 3 of the 5 year ends shown that have a P/S, its P/S ranged from 1.9x in 2025 to 2.7x in 2023.
| Year end | Price | P/E | P/S | P/B |
|---|---|---|---|---|
| 2025 | $7.04 | 50.8x | 1.9x | 1.8x |
| 2024 | $7.37 | N/A | 2.2x | 1.9x |
| 2023 | $7.83 | N/A | 2.7x | 2.0x |
| 2022 | $4.94 | N/A | N/A | 1.2x |
| 2021 | $9.52 | N/A | N/A | 2.1x |
GNG Valuation
| GNG view | Overvalued |
|---|
GNG fair value is part of GNG Pro. See plans
Frequently Asked Questions About LFST
What is LFST's forward P/E ratio?
Lifestance Health Group has a forward P/E ratio of 61.4x.
Is LFST stock overvalued?
GNG's valuation label for LFST is Overvalued. Its P/E of 52.0x compares with a median of 24.2x across 12 similar companies.
What is LFST's price to sales ratio?
Lifestance Health Group has a price to sales ratio of 3.3x.
LFST pages: Overview, Earnings, Forecast, Financials, Valuation, Competitors